Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03039686 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT03039686 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 166 participants.
The verdict
NCT03039686, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).
Interventions
- DRUG RO7239361
- DRUG Placebo for RO7239361
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2020-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03039686
The ClinicalTrials.gov registry entry for NCT03039686 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RO7239361 is the first listed.
NCT03039686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03039686 about?
NCT03039686 is a clinical study titled "Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy". This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).
What is the current status of trial NCT03039686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2017-07-06. Estimated completion is 2020-04-28.
What interventions are being tested in trial NCT03039686?
The interventions under investigation include: RO7239361 (DRUG), Placebo for RO7239361 (DRUG).
Who is sponsoring clinical trial NCT03039686?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.